Study record at a glance
| Study ID | texas-impact |
|---|---|
| Design | Planned state-directed ibogaine drug-development clinical trials; final protocol and implementation details remain in development |
| Condition / topic | Addiction, traumatic brain injury, and behavioral health |
| Population | The broader program description covers addiction, traumatic brain injury, and behavioral health; the cited HHSC page does not define an enrolled population |
| Sample size | Not announced on the cited HHSC program page |
| Comparator | Not announced on the cited HHSC program page |
| Follow-up | Not announced on the cited HHSC program page |
| Outcome focus | Program-level development of controlled ibogaine research; no study-specific registered outcome set is identified in the cited program source |
What it suggests
Texas has selected UTHealth Houston to lead implementation of Senate Bill 2308 and is developing the institutional path for future ibogaine clinical trials
What it cannot establish
A funded or planned program cannot establish safety or efficacy. The HHSC page does not establish a final protocol, enrollment size, comparator, follow-up, or outcomes, and says contract development and requirement issues remain
Recruitment relevance
Enrollment has not opened. HHSC directs interested people to check its program page for later updates and contact information after trials are approved
Do not travel, discontinue medication, or change care based on this summary. The sponsor and the current primary source govern participation decisions.
How this summary was framed
This record reports the design and registered or officially announced research question before interpretation. Unknown sample, comparator, follow-up, and outcome details remain marked as unknown. The Atlas does not infer results from recruitment status, regulatory acceptance, funding, or study completion.